1800 244 735

Helpline (02) 9874 9777

2015 Huntington's Disease Therapeutics Conference: Day 2

Our second update from the Annual Huntington’s Disease Therapeutics Conference.

Wednesday: huntingtin-lowering drugs

09:03 – This morning’s session is focused on what many scientists consider the most promising approach to HD therapy, “Huntingtin silencing” or huntingtin lowering

09:06 – The idea with Huntingtin silencing is to reduce the creation of the mutant huntingtin protein in cells, using a variety of techniques.

09:06 – For much more on this topic, see: http://en.hdbuzz.net/topic/29

09:07 – Basically, every HD patient has a mutant HD gene. That gene is copied by the cell into a messenger RNA molecule, a working copy of the gene

09:08 – The RNA molecules are used by the cell as templates to create proteins. So: Mutant HD gene -> mutant HD messenger RNA -> mutant HD protein

09:09 – In theory, we could interfere with this chain at any point and have the same effect – reducing the levels of the mutant HD protein.

09:11 – George McAllister, of BioFocus, is leading a project that’s looking for chemicals that reduce levels of mutant huntingtin protein

09:12 – His company is screening a massive number of chemicals: applying them to cells and seeing whether they reduce mutant huntingtin levels

09:15 – New technologies developed over the last few years let BioFocus use real human cells and measure infinitesimal levels of mutant huntingtin

09:32 – BioFocus is screening thousands of molecules, looking for one that reduces mutant huntingtin protein levels without making cells sick

09:35 – This is an interesting approach, they’re looking for chemicals that reduce mutant huntingtin without necessarily knowing how they’re working

09:41 – It’s a cool way to look for drugs that work in ways you might not predict, which is a good way to learn about new approaches to the problem

09:46 – Dean Stamos, of Vertex Pharmaceuticals, addresses the conference on his companie’s efforts to come up with drugs to reduce mutant huntingtin

09:47 – Vertex discovered chemicals that block the activity of a protein called “Hsp90” had the result of reducing mutant huntingtin levels

09:50 – These chemicals turned out to not be good drugs, but could still teach us about how cells get rid of tricky proteins like mutant huntingtin

09:55 – Cells have very sophisticated ways of dealing with proteins, like mutant huntingtin, that don’t fold up correctly.

09:57 – A number of tiny machines called “heat shock proteins” help cells keep all their proteins folded up in the correct shape, even after stress

10:00 – Hsp90 is “heat shock protein 90”, Vertex developed specific molecules to block it, leading to long-term reduction of mutant huntintin

10:01 – For reasons they haven’t specified, Vertex doesn’t feel like these drugs would be good for long-term use

10:06 – Lisa Stanek, Genzyme, is using primates to develop techniques for silencing mutant huntingtin using viral delivery of something called siRNA

10:09 – siRNA’s are ‘small interfering RNA’; short pieces of RNA (a cousin of DNA) that likes to pair up with specific RNA molecules in the cell

10:10 – Once in the cell, siRNA molecules find and destroy the huntingtin messenger RNA molecules, in turn reducing huntingtin protein levels

10:12 – They’re using tiny, harmless, viruses that are good at getting siRNA into brain cells. These viruses are called “adeno-associated viruses”

10:17 – Stanek reminds the audience that treating mouse brains is pretty easy, but human brains are more than 1,000 times larger!

10:18 – To study this, we need to work in animals that have larger brains. Stanek’s team has been working in primates to see how these viruses work

10:21 – Genzyme is conducting careful study of the safety of their viruses in monkeys – if there are any problems we want to catch them now.

10:26 – Trial injections of the viruses Genzyme wants to use for human trials give really impressive spread of the virus throughout the brain!

10:29 – This is exciting, one of the hurdles for this approach in the past was the relatively limited spread of injected virus within the brain

10:31 – Careful observation of injected monkeys revealed no health concerns for a month after they received their brain injections of test virus

11:06 – Next Geoff Nichol from Sangamo Biosciences is giving an update on ‘Zinc Finger’ drugs to reduce production of the mutant huntingtin protein

11:07 – More on zinc finger drugs here http://en.hdbuzz.net/103

11:10 – Zinc finger drugs aim to switch off production of the mutant protein at its source. They stick to the DNA of the gene inside cells

11:10 – After sticking, the mutant protein gene is switched off.

11:11 – What’s more, the zinc finger drugs can switch off the mutant copy of the gene, while leaving the healthy copy alone

11:12 – Leaving the healthy huntingtin gene alone is very appealing because switching it off might cause unwanted side effects – but we don’t know.

11:16 – Sangamo has partnered with Shire Pharmaceutials to develop their zinc finger drugs

11:16 – The zinc finger drug is injected into the brain as a ‘recipe’ carried by a harmless virus.

11:17 – The virus takes up residence in brain cells and the cells themselves become a factory for making the zinc finger drug

11:18 – This means that in theory at least the zinc finger drugs could be a one-shot solution to prevent or slow HD.

11:18 – The flipside of that is that if there are unwanted effects, those will be longlasting too – so it’s important to test these drugs carefully

11:19 – So far, the zinc finger drugs have been tested in several different mouse models of mice and look to be safe and effective.

11:19 – Figuring out how to deliver the drugs safely to the brain is the next big challenge for Sangamo and Shire.

11:21 – A clinical trial of zinc finger drugs is currently in the early planning stages, probably in patients with early symptoms

11:41 – Frank Bennett, of Isis Pharmaceuticals, addresses the conference on his companies efforts with drugs called “antisense oligonucleotides”

11:43 – These “ASO” molecules are another way to destroy specific RNA molecules, helping reduce the levels of a protein we want to get rid of

11:44 – Isis has been working to develop ASO molecules that destroy the huntingtin RNA, and therefore reduce huntingtin protein levels

11:47 – Isis has proven in a large number of animal studies that reducing huntingtin in the brain using ASOs improves HD-like symptoms in mice

11:48 – Isis has experience with these types of molecules – they’ve treated more than 6,000 human patients in 100 clinical studies for other diseases

11:49 – Like many other drugs discussed today, ASOs can’t get into the brain from the blood, so they need to be injected into it somehow

11:51 – To get into the brain, injections can be made at the base of the spine into the spinal fluid, which carries drugs to the brain

11:51 – This approach has been used in multiple human studies conducted by Isis for other diseases, and so far seems safe and effective.

11:52 – In mice treated with ASOs targeting huntingtin, the effect of the drug lasts for months without needing to be re-dosed.

11:56 – Like the other companies here today, Isis has already conducted detailed safety studies in primates

12:02 – As an extra check of their plan for delivery, Isis has done spinal delivery in pigs, who apparently have pretty long spinal cords!

12:05 – Will ASOs work in people? Isis has a program in a disease called Spinal Muscular Atrophy where the drug is being delivered similarly

12:07 – Brain and spinal cord tissue from Spinal Muscular Atrophy patients show that ASOs effectively get into the brain after spinal fluid delivery

12:09 – Though the numbers of patients are small, kids with spinal muscular atrophy treated with Isis' drugs seem to be showing disease improvement

12:11 – Isis is launching a human HD study, starting sometime in the first half of 2015! The drug is called “HTT-Rx”, and the study is focused on safety.

12:13 – This first trial will have the goal of establishing that Htt-Rx delivery to the human brain and spinal cord is safe.

12:15 – What a morning! All these silencing approaches look like very exciting approaches for treating HD, and the technology has really advanced!

12:22 – Doug Macdonald, CHDI, is leading the foundations efforts to look for “biomarkers” for the huntingtin silencing studies. What’s a biomarker?

12:23 – If we silence the huntingtin protein in the brain, how we will know the drugs worked? We can’t very well take brain tissue samples to check

12:24 – So Macdonald is leading efforts to look for other ways to see the effect of silencing drugs in human brains.

12:25 – One way is to measure levels of the huntingtin protein in fluids we can get to, like the spinal fluid. Sampling this is pretty easy.

12:27 – Using rats, CHDI and Isis are testing whether levels of the huntingtin protein in the spinal fluid change after delivery of silencing drugs

12:30 – Data hot off the presses suggests it’s possible that levels of the huntingtin protein in the spinal fluid somewhat mirror brain levels

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more